|Year : 2018 | Volume
| Issue : 1 | Page : 17-27
An interplay between MicroRNA and SOX4 in the regulation of epithelial–mesenchymal transition and cancer progression
Anjali Geethadevi1, Ansul Sharma2, Manish Kumar Sharma3, Deepak Parashar1
1 Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
2 Department of Anatomy, All Institute of Medical Sciences, New Delhi, India
3 Department of Biotechnology, I.P. College, Bulandshahr, Uttar Pradesh, India
|Date of Submission||15-Jan-2018|
|Date of Acceptance||14-Feb-2018|
|Date of Web Publication||26-Feb-2018|
Dr. Deepak Parashar
Department of Obstetrics and Gynecology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226
Source of Support: None, Conflict of Interest: None
MicroRNAs (miRNAs) are abundant class of small, noncoding RNAs which are emerging as a potential therapeutic target for various cancers. Sex-determining region Y-related high-mobility group box 4 (SOX4) is an important member of SOX family and a crucial master regulator of epithelial–mesenchymal transition (EMT) that has been implicated in tumor growth and progression. In cancers of epithelial origin and in some others, growing evidence has revealed a close association between miRNAs and SOX4. Most miRNAs are reported to modulate SOX4 by directly binding to SOX4 3'-untranslated region, thereby regulating cancer cell proliferation, invasion, and EMT. In this review, we highlight the interaction of miRNAs with SOX4 in various cancers and discuss the possibility of combined miRNA-SOX4-based therapeutic approach that may serve as a targeted therapy for several cancers.
Keywords: Cancer, epithelial–mesenchymal transition, microRNA, SOX4
|How to cite this article:|
Geethadevi A, Sharma A, Sharma MK, Parashar D. An interplay between MicroRNA and SOX4 in the regulation of epithelial–mesenchymal transition and cancer progression. Cancer Transl Med 2018;4:17-27
|How to cite this URL:|
Geethadevi A, Sharma A, Sharma MK, Parashar D. An interplay between MicroRNA and SOX4 in the regulation of epithelial–mesenchymal transition and cancer progression. Cancer Transl Med [serial online] 2018 [cited 2018 Jun 20];4:17-27. Available from: http://www.cancertm.com/text.asp?2018/4/1/17/226171
| Introduction|| |
Metastasis is the primary cause of mortality and morbidity in various types of cancers. It is a complex process, during which cancer cells disseminate from primary tumor through the circulation and establish their growth at distant organs. In comparison to benign tumors, metastatic tumors are difficult to remove by surgical resection and/or by irradiation, are resistant to treatment with chemotherapeutic drugs, and hence often have poor prognosis. Besides, chemotherapeutics are developed in such a way to target proliferation of cancer cells rather than dissemination. Hence, there is an utmost need to develop potential therapeutics, targeting or inhibiting the metastasis of cancer cells.
| Epithelial–Mesenchymal Transition: A Critical Player in Metastasis|| |
Despite various advancements in therapeutics, recurrence due to metastasis remains a common issue for cancer patients. Cancer recurrence and metastasis are often associated with epithelial–mesenchymal transition (EMT). EMT is a significant regulatory process during normal embryogenesis as well as in cancer progression and metastasis, wherein differentiated epithelial cells change to dedifferentiated and migratory mesenchymal state., EMT is often displayed by cancer stem cells (CSCs) which are self-renewing and heterogeneous population of cells that usually remain in resting phase, thus chemoresistant.,,, Hence, there is an urgent need of prognosis detecting EMT – a characteristic of CSCs – and thereby regulating metastatic growth and mortality. EMT is characterized by several hallmark processes such as loss of cell–cell adhesion and downregulation of epithelial markers such as E-cadherin expression and components of tight junction and increase in mesenchymal markers such as N-cadherin and vimentin expression. These events occur in conjunction with the upregulation of several transcription factors such as Snail, Twist, SOX, and ZEB by regulating epithelial and mesenchymal markers at transcriptional level. Snail1 induces EMT by inhibiting other epithelial markers that affect E-cadherin and bind to the E-cadherin promoter to inhibit its transcription. Twist induces EMT by repressing E-cadherin by inducing Snail1 or Snail2 followed by binding to its promoter. The ZEB family which includes ZEB1 and ZEB2 induces EMT by activating mesenchymal markers such as N-cadherin and vimentin and repressing epithelial markers E-cadherin, gap junctions by binding to E-box sequences in the E-cadherin promoter, and recruiting co-repressors such as SWI/SNF, NuRD, and CtBP. SOX transcription factors synergize with SNAIL1 or SNAIL2 in promoting EMT. Furthermore, the key signaling pathway regulating EMT is the transforming growth factor-β (TGF-β) pathway. TGF-β is produced by immune and nonimmune cells and induces EMT in Smad dependent and independent pathway which eventually regulates Snail and Twist at transcriptional level. The oncogenic consequences of TGF-β during late tumorigenesis that eventually leads to EMT are mediated by PI3K/Akt axis. Other pathways that integrate with TGF-β to induce EMT are Wnt/-β-catenin, Notch pathway, and integrin-linked kinase (ILK) and integrin signaling pathway.
| SOX4 As A Master Regulator of Epithelial–Mesenchymal Transition and its Role in Cancer Progression|| |
Sex-determining region Y-related high-mobility group box 4 (SOX4) is one of the master transcription factors, which regulates EMT and contributes to cell survival and metastasis, by TGF-β-induced upregulation of mesenchymal EMT markers such as vimentin and N-cadherin,, and loss of epithelial markers such as E-cadherin [Figure 1] via transcription factor repressors – Snail, ZEB, and Twist, or via an epigenetic regulator – polycomb-group protein enhancer of zeste homolog 2 (EZH2).,
|Figure 1: Interplay between SOX4 and microRNA in epithelial–mesenchymal transition in cancer. Red arrows: Overexpression of gene expression or protein expression. Green arrows: Downregulation of gene expression or protein activity|
Click here to view
SOX4 is a 47-kDa protein member of the Sex-determining region Y-related high-mobility group box (SOX) transcription factor family, and the gene is located on chromosome 6p22.3 which encodes a protein of 474 amino acids with three distinct domains: an high-mobility group (HMG) box-DNA-binding region, a glycine-rich region which is a novel functional region for promoting apoptotic cell death, and a serine-rich region that acts as a transactivation domain [Table 1]., SOX4 is a necessary transcription factor in many embryonic development processes such as the thymocyte differentiation, B-cell development, T-cell development, pancreatic cell differentiation, osteoblast differentiation, in the development of nervous system and embryonic cardiovascular system,, and survival of multipotent neural cells and mesenchymal stem cells, thereby functioning as a putative stem cell marker crucial for cell fate determination. Many genes that are involved in embryogenesis have also been implicated in tumorigenesis. Among the 20 members of SOX family, SOX4 has been recognized as a “cancer signature gene” based on its oncogenic role in multiple human cancers; majority having epithelial origin such as in breast cancer, ovarian cancer, lung cancer, hepatocellular carcinoma (HCC), and some others such as sarcomas [Figure 1]. In normal adults, expression of SOX4 is restricted to certain cell types, including hematopoietic stem cells, mammary stem cells, and hair follicle stem cells.,, Of note, several lines of evidence suggest that SOX4 overexpression could promote tumor progression by inhibiting apoptosis, cell proliferation, and cell survival; expansion of CSCs; and initiation of EMT through regulating transcription of genes involved in cancer signaling pathways such as Wnt/β-catenin pathway, Notch1 pathway, and p53 pathway, [Figure 2] or by interaction with several microRNAs (miRNAs) components of miRNA processing machinery such as dicer, argonaute 1, and RNA helicase A., In contrast, SOX4 can also serve as a tumor suppressor which is evident from the fact that increased expression of SOX4 has been found to correlate with slower cancer progression, hence prolonged patient survival in bladder cancer, colon carcinoma, HCC, melanoma, and gallbladder cancer,,, by inhibition of tumor initiation through DNA damage signaling or direct transcriptional regulation of dicer and/or activation of apoptosis. This differential expression of SOX4 in various tumor types may relate to either amplification of SOX4 chromosome loci such as in bladder and lung cancer, or activity of signaling pathways such as TGF-β and Wnt, hormone regulation such as in breast cancer, and posttranscriptional modifications or may occur through miRNA-mediated regulation of SOX4 mRNA stability and protein translation.
|Figure 2: SOX4/microRNA interaction in cancer. Red arrows: Overexpression of gene expression or protein expression. Green arrows: Downregulation of gene expression or protein activity. Red arrows: Inhibition of gene expression or protein activity|
Click here to view
|Table 1: Different domains of sex determining region Y-box 4 with their functions and interaction partners|
Click here to view
| Micro-RNAs Directly Target SOX4 to Regulate Cancer Progression|| |
miRNAs are small (18–25 nucleotides in length) class of endogenous noncoding RNAs that regulate gene expression by binding to 3'-untranslated region (3'-UTR) of their target messenger RNAs (mRNAs), thereby either degrading or suppressing their translation. miRNAs are critical regulators of cell proliferation, differentiation, metabolism, and apoptosis in normal cells. Deregulation of miRNAs such as downregulation or aberrant amplification/deletion of miRNA mapped to genomic loci has been implicated in tumorigenesis, making them either tumor suppressors or oncogenes, respectively., Most miRNAs have been observed to be downregulated in many human cancers. Recent studies have demonstrated that miRNAs can modulate SOX4; moreover, SOX4 also regulates the expression of several miRNAs. Most of the miRNAs are reported to be downregulated in many cancers that causes an upregulation of SOX4. In this review, we provide a comprehensive overview of interactions between miRNAs and SOX4 and their roles in various cancers while focusing on how we can utilize this knowledge in developing novel cancer therapies. Functions of these miRNAs in cancer progression and metastasis are discussed below.
miR-338-3p is located on chromosome 17q25.3 on 7th intron of apoptosis-associated tyrosine kinase gene. Recent studies have identified that miR-338-3p is downregulated in gastric cancers, ovarian cancer, breast cancer, colorectal cancers (CRCs), highly metastatic non-small cell lung carcinoma (NSCLC) cells, and metastatic tissue specimens. Recently, Sun et al. reported that downregulated miR-338-3p enhanced proliferation and suppressed apoptosis in NSCLC by targeting RAB14. Overexpression experiments caused suppression of cancer cell migration, invasion, and EMT through directly targeting SOX4 on 3'-UTR and decreasing its mRNA and protein expression both in vitro and in vivo. Of note, upregulation of miR-338-3p also reported to inhibit cell proliferation, migration, and invasion of renal cell carcinoma (RCC) and breast cancer and caused downregulation of SOX4, thereby modulating SOX4 mRNA and protein levels. The authors suggest that miR-338-3p and SOX4 expression are inversely correlated in NSCLC, RCC, and breast cancer. Furthermore, Li et al. found that histone 3 (H3) lys27 (H3K27me3) methylation but not DNA methylation unlike in gastric cancer is activated in the promoter region of miR-338-3p, which is responsible for downregulation of miR-338-3p, suggesting an epigenetic regulatory mechanism of this miRNA in cancer progression.
miR-25 is located on chromosome 7 (7q22.1) in the 13th intron of the MCM7 gene and is a member of the miR-106b-25 cluster (consisting of miR-106b, miR-25, miR-93, miR-363-3p, and miR-367). miR-25 functions as an oncogene in NSCLC, breast cancer, ovarian cancer, cervical cancer, and gastric cancer, whereas it acts as a tumor suppressor in colon cancer and glioblastoma multiforme. Recent studies by Chen et al. revealed that miR-25 acts as tumor suppressor which is evident from the fact that miR-25 is downregulated in osteosarcoma and is associated with advanced tumor–node–metastasis stage and lymph node metastasis. However, introduction of miR-25 by overexpression experiments showed suppression in cell proliferation, migration, and invasion of osteosarcoma cells in vitro and in vivo. This study also showed a direct association of miR-25 with SOX4 using bioinformatics analysis and luciferase reporter assay. Furthermore, this tumor suppression effects of miR-25 is partially reversed by SOX4 following interaction, thus suggesting an inverse correlation of miR-25 with SOX4 expression in osteosarcoma tissues.
miR-138 is known to be frequently downregulated in CRC, esophageal cancer, bladder cancer, and NSCLC through PD-L1 downregulation, repression of EZH2 or targeting YAP1.,, Recent studies showed that downregulated miR-138 is associated with increased expression of SOX4 and upregulation of miR-138 inhibited proliferation, invasion, metastasis, and EMT of NSCLC cells and highly invasive ovarian cancer cells both in vitro and in vivo. In addition, authors used bioinformatic analyses such as Target Scan and luciferase reporter assay to predict that SOX4 is a direct potential target of miR-138, which binds to 3'-UTR of SOX4 mRNA. Hence, based on this study, miR-138 negatively regulates SOX4. Furthermore, earlier studies reveal that SOX4 can suppress the effects of p53 as p53 being a downstream target of SOX4. Li et al. also demonstrated that in NSCLC cells, decreased SOX4 expression could increase the level of miR-138 via upregulation of p53. Hence, introduction of miR-138 inhibited growth, invasion, and EMT of NSCLC cells through SOX4/p53 feedback loop. Similar results were shown by other studies in ovarian cancer providing substantial evidence of miR-138 to be used for suppression of NSCLC as well as ovarian cancer by targeting SOX4 via p53 [Figure 2].,
Reports have identified miR-129-5p deregulation in some cancers such as esophageal cancers and chondrosarcoma, which resulted in upregulation of SOX4. A recent study by Zhang et al. demonstrated that overexpressed miR-129-5p caused suppression of cell proliferation, migration, and promoted apoptosis both in vitro and in vivo xenograft models by targeting SOX4 and causing its downregulation. Aberrant Wnt/β-catenin signaling has been observed in many cancers including chorndrosarcoma and is associated with SOX4 in melanoma cells. Moreover, miR-129-5p also inhibited over-activation of Wnt signaling components such as β-catenin, cyclin D1, and c-Myc by targeting SOX4 bringing about regulation of proliferation and migration in chondrosarcoma cells.
miR-129-2 is located on chromosome 11 at locus 11p11.2. miR-129-2 is often reported to be downregulated in bladder cancers, CRC, β-catenin/TCF-mediated hepatocarcinoma, gastric cancer, endometrial cancer, and esophageal cancer cells and adjacent nontumor tissues from patients who underwent primary surgical resection for esophageal cancer and correlates with advanced TNM stage in esophageal cancers. This is further associated with increased expression of SOX4 and SOX4-mediated epigenetic silencing of miR-129-2. SOX4 is found to be inversely correlated with epigenetic repression of miR-129-2; however, restoration of miR-129-2 brought a downregulation of its direct target-SOX4 expression along with a reduction in migration, proliferation, and cell arrest of the cancer cells.,,
miR-449a is a member of miR-34/miR-449 family consisting of miR-34a, miR-34b, miR-34c, miR-449a, miR-449b, and miR-449c. Notably, one of its family members miR-34a is the first currently tested miRNA in a clinical trial for patients with primary liver cancer. miR-449 is known as a tumor suppressor in prostate cancer, gastric cancer, bladder cancer, lung cancer, and HCC. Sandbothe et al. in their recent study demonstrated an epigenetic regulation of miR-449a induced by TSA-mediated histone deacetylase (HDAC) inhibition in HCC and normal liver cell lines, suggesting a regulation by histone acetylation. Using target gene prediction databases, the authors identified putative targets for miR-449 family members and SOX4 to be among one of the targets, which is overexpressed in HCC tissues and has poor prognosis. Moreover, the authors have also shown that overexpression of miR-449 family members was inhibited by TGF-β-mediated SOX4 overexpression which further inhibits cell migration.
miR-381 is reported to be a tumor suppressor which is downregulated in breast cancer, chondrosarcoma, osteosarcoma, and ovarian cancer through targeting Cx43, VEGF-C, LRRC4, and YY1. In a recent novel study, Zhang et al. identified miR-381 to be downregulated in gastric cancer. However, overexpression of miR-381 inhibited migration and invasion and EMT in gastric cancer cells through direct targeting and downregulating SOX4. Mechanistic studies by Zhang et al. revealed that a long noncoding RNA taurine 1 (TUG1) negatively regulates miR-381 expression in gastric carcinoma [Figure 2].
Earlier, miR-204 is known to suppress tumor initiation in esophageal cancer, lung cancer, and gastric cancer.,, Few known targets of miR-204 are USP47, SOX4, RAB22A, SIRT1, and Snai1.,, In a very recent study, Yuan et al. reported that miR-204 suppressed gastric cancer cell proliferation and metastasis and negatively correlate with its target SOX4. Further, a comprehensive analysis with clinicopathological parameters of gastric cancer patients revealed that miR-204 and SOX4 are associated with lymph node metastasis and tumor Stages I–IV. Another study by Yin et al. identified downregulation of miR-204 in T-cell acute lymphoblastic leukemia and overexpression by mimics inhibited the cell proliferation, migration, and invasion ability and SOX4 expression, thereby negatively modulating SOX4 expression by binding to its 3'-UTR.
A recent study identified that frequent downregulation of miR-320 occurs in primary colon cell carcinoma (CRC) tissues and cell lines. Lentiviral-mediated overexpression of miR-320 is reported to inhibit HCT116 CRC growth and migration in vitro and inhibit tumor formation in SCID mice. Furthermore, there exists an inverse correlation between the expression of miR-320 and its targets such as SOX4, FOXM1, and FOXQ1.
Like other miRNAs discussed here, miR-363-3p and miR-140 are tumor suppressors which are downregulated in CRC tissue specimens with lymph node metastasis and gastric cancer tissues and cell lines, thus promoting cell migration and invasion and EMT induction both in vitro and in vivo via its direct target SOX4. Hu et al. further demonstrated that exogenous miR-363-3p reversed the EMT and phenotypic metastasis in CRC cells. Zhou et al. revealed that miR-140 overexpression in HGC-27 cells inhibited SOX4 expression, resulting in decreased cell viability, colony formation, and resulted in G0/G1 cell arrest.
A recent study by Zhang et al. has shown that miR-187 is downregulated in CRC cell lines and tissues and SOX4 is upregulated which is correlated with poor disease prognosis. On the contrary, exogenous miR-187 can inactivate TGF-β-mediated Smad pathway, thus preventing EMT and suppressing cell proliferation and migration in vitro, and inhibit CRC growth and progression in vivo. Furthermore, authors also found SOX4-upstream effector of Smad as a direct target of that miR-187.
Several studies revealed miR-191 to be an estrogen and hypoxia responsive miRNA that promotes estrogen receptor-positive breast cancer cell proliferation and migration. Apart from its role in breast cancer, miR-191-5p has been identified in other cancers such as lung cancer, colon cancer, and gastric cancer as an oncogenic miRNA. A recent study by Sharma et al. demonstrated that p53 downregulates miR-191-5p in breast cancer, whereas SOX4 – a direct target of miR-191 – increases p53 protein levels. In fact, overexpression of miR-191 caused a downregulation of SOX4 and p53 levels.
| Microrna-212 And Microrna-132|| |
miR-212 and miR-132 are located in chromosome 17 and is derived from the miR-212/132 cluster. Earlier studies reported that miR-212 and miR-132 are tumor suppressor and are downregulated in ovarian cancer by targeting E2F5 and HBEGF and NSCLC by targeting SOX4. SOX4 is a downstream effector of miR-212 and miR-132 modulating EMT of ovarian cancer cells. A recent study by Lin et al. identified that SOX4/EZH2 complex can silence miR-212/132 expression by binding to its promoter region and promoting H3K27me3, whereas miR-212 and miR-132 can directly bind to the 3′UTR of SOX4, suppress its expression, and thus form a miR-132/212-SOX4/EZH2-H3K27me3 feedback loop in ovarian cancer cells. EZH2 is a subunit of the polycomb repressor complex 2 that promotes DNA methylation. In addition, EZH2 can catalyze H3 (H3K27me3) trimethylation, an epigenetic modification that silences gene transcription. Therefore, the downregulation of miR-212 and miR-132 in ovarian cancer cells is due to epigenetic upregulation of EZH2 and SOX4. The authors further showed an interaction between EZH2, SOX4, and HDAC3 that form a co-repressor complex to silence miR-212 and miR-132 expression in ovarian cancer cells. Exogenous introduction of miR-132 significantly inhibits proliferation and EMT and induces cell cycle arrest and apoptosis in ovarian cells and osteosarcoma cells [Figure 1] and [Figure 2].
| Microrna-211|| |
miR-211 plays a dual role as a tumor suppressor in epithelial ovarian cancer, HCC, and breast cancer,, as well as an oncogene in colon cancer, oral carcinoma, head and neck squamous cell carcinoma, often associated with poor prognosis of patients. In one of the studies in gastric cancer, Wang et al. demonstrated that miR-211 is downregulated and its overexpression inhibited gastric cancer cell proliferation and invasion in vitro by targeting and downregulating SOX4. This highlights the role of miR-211 as a tumor suppressor by interacting with SOX4.
miR-30a plays an important role in development of endometrial carcinoma, HCC, and chronic myelogenous leukemia. One of the recent studies has shown that miR-30a is downregulated in chondrosarcoma patients and is negatively correlated with SOX4 expression. miR-30a directly targets SOX4 and its overexpression downregulates SOX4 expression, thereby suppressing proliferation, migratory, and invasive capacity of SW1353 chondrosarcoma cells in vitro and TGF-β-mediated EMT in prostate cancer cells.
miR-133a is a muscle-specific miRNA where the gene is located on chromosome 18 and chromosome 20 as two copies. Several studies have shown that low levels of this miRNA are expressed in several cancers including ovarian cancer, CRC, lung cancer, breast cancer, prostate cancer, and esophageal cancer. Li et al. have demonstrated that miR-133a is downregulated in esophageal squamous cell carcinoma (ESCC) cell lines and clinical ESCC tissue samples and is inversely correlated with tumor progression in ESCCs, suggesting that miR-133a may function as a novel tumor suppressor. Furthermore, SOX4 is reported to be a direct target of miR-133a with the 3'-UTR, thereby regulating EMT markers as well. Notably, there is a reciprocal effect of miR-133a over tumor progression upon targeting SOX4, similar to other miRNAs discussed above. For instance, following overexpression of miR-133a, SOX4 is decreased thereby decreasing migration and invasion and EMT in ESCC which clearly suggests that miR-133a could act as a potential tumor suppressor in ESCC through targeting SOX4 and the EMT process.
| Concluding Remarks and Future Directions|| |
Challenges faced in curbing metastasis and developing prognostic tools are mainly due to the clinical and molecular heterogeneity of tumor cells exhibiting EMT. Not all cells undergo EMT simultaneously and the cells which have undergone EMT not usually metastasize simultaneously. In fact, extracellular and intracellular cues, environmental changes, and epigenetic factors affect the EMT and metastatic process. Drug resistance is another serious issue that accompanies EMT and metastasis. For instance, in breast and pancreatic cancer, higher resistance to drugs such as oxaliplatin and paclitaxel, is reported to be seen in cells expressing EMT markers. Therefore, a more robust prognostication is required to overcome this challenge. In recent years, miRNA-based therapy is emerging rapidly. For instance, high level of Ki-67 is used as a prognostic marker; however, miR-21 has gained popularity and can be used as a prognostic marker due to the fact that a similar high level of this miRNA can be seen in liver cancer; therefore, in place of Ki-67, miR-21 can be used as a cancer biomarker and marker for metastasis. Recent studies reveal that exosomes released from the tumor milieu may mediate cell-to-cell communication that can be exploited to inhibit tumor growth by delivering antitumor therapeutics such as miRNAs packed in nanoliposomes or exosomes. Therefore, miRNA packed in exosomes can be promising therapeutic approach.
In this review, we have discussed the role of various tumor suppressor miRNAs in regulating a significant transcription factor, SOX4, also known as a master regulator of EMT in different cancers. We also highlighted the importance of their interplay in regulating cancer cell proliferation, migration, and EMT. These miRNAs regulate SOX4 directly via components of multiple signaling pathways such as Hedgehog pathway, Notch pathway, TGF-β pathway, and Wnt/β-catenin pathway [Table 2]. SOX4 is often reported to be overexpressed in many aggressive cancers. Many recent studies have reported that miRNAs which are particularly tumor suppressors modulate the function of SOX4 by binding to 3'-UTRs and initiate their degradation at translational level, thus downregulating its expression as well as tumor growth and proliferation both in vitro as well as in vivo. In fact, there exists an inverse correlation between various miRNAs and SOX4 in most of the cancers. For instance, miRNAs that are downregulated in various aggressive cancers predominantly of epithelial origin and some of nonepithelial ones correlated with an upregulation of SOX4 expression levels, thereby adding to the aggressiveness of the cancer phenotype. Some studies reported that epigenetic repression of miRNAs can lead to overexpression of SOX4, and exogenous expression of these miRNAs can downregulate SOX4 expression and potentially inhibit metastasis in vitro and in vivo by inhibiting cancer cell proliferation, migration, and invasion and induce apoptosis., Notably, this suggests that miRNA–SOX4 overexpression and downregulation switch may serve as a prognostic marker for cancer patients. It is fundamental to delineate the interplay between miRNAs and SOX4 to understand the mechanisms involved in EMT. This can further our understanding of cancer progression and metastasis. Further research is required to understand the molecular mechanism and the epigenetic mechanism involved in the interaction of various miRNAs with SOX4 to develop novel anticancer therapeutic approaches that involve modulation of miRNA–SOX4 interaction by epigenetic drugs. In summary, miRNA–SOX4 interplay highlighted here provides critical insights into the regulatory networks by which miRNA regulates the transcription factor – SOX4 and how their interaction can modulate critical cell-fate and metastatic event called EMT. Remarkably, in the future, upregulation/restoration of tumor suppressor miRNAs along with downregulation of SOX4 with an epigenetic approach or signaling pathway-targeted approach could possibly evolve as a promising option to improve patient survival and decrease mortality.
|Table 2. MicroRNAs that directly regulate sex determining region Y-box 4 in various cancers and functions they perform upon interaction with sex determining region Y-box 4|
Click here to view
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science
2013; 342 (6159): 1234850.
Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest
2003; 112 (12): 1776–84.
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest
2009; 119 (6): 1420–8.
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene
2010; 29 (34): 4741–51.
Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature
2015; 527 (7579): 472–6.
Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol
2017; 14 (10): 611–29.
Zheng L, Zhou Z, He Z. Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer. Int J Clin Exp Pathol
2015; 8 (11): 14005–12.
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol
1991; 113 (1): 173–85.
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol
2014; 15 (3): 178–96.
Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, Zhang J, Han B. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro
. Prostate Cancer Prostatic Dis
2013; 16 (4): 301–7.
Yu CC, Chen PN, Peng CY, Yu CH, Chou MY. Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis. Oncotarget
2016; 7 (15): 20180–92.
Vervoort SJ, Lourenco AR, van Boxtel R, Coffer PJ. SOX4 mediates TGF-beta-induced expression of mesenchymal markers during mammary cell epithelial to mesenchymal transition. PLoS One
2013; 8 (1): e53238.
Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schubeler D, van Nimwegen E, Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell
2013; 23 (6): 768–83.
Ishiwata T. Cancer stem cells and epithelial-mesenchymal transition: novel therapeutic targets for cancer. Pathol Int
2016; 66 (11): 601–8.
Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, Escriva M, Hernandez-Munoz I, Di Croce L, Helin K, Garcia de Herreros A, Peiro S. Polycomb complex2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol
2008; 28 (15): 4772–81.
Koumangoye RB, Andl T, Taubenslag KJ, Zilberman ST, Taylor CJ, Loomans HA, Andl CD. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer
2015; 14: 24.
Chen J, Ju HL, Yuan XY, Wang TJ, Lai BQ. SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis. Clin Transl Oncol
2016; 18 (1): 65–72.
Jafarnejad SM, Ardekani GS, Ghaffari M, Li G. Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis. Cell Mol Life Sci
2013; 70 (15): 2677–96.
Vervoort SJ, van Boxtel R, Coffer PJ. The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe? Oncogene
2013; 32 (29): 3397–409.
Schilham MW, Oosterwegel MA, Moerer P, Ya J, de Boer PA, van de Wetering M, Verbeek S, Lamers WH, Kruisbeek AM, Cumano A, Clevers H. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature
1996; 380 (6576): 711–4.
Schilham MW, Moerer P, Cumano A, Clevers HC. Sox-4 facilitates thymocyte differentiation. Eur J Immunol
1997; 27 (5): 1292–5.
Mavropoulos A, Devos N, Biemar F, Zecchin E, Argenton F, Edlund H, Motte P, Martial JA, Peers B. Sox4b is a key player of pancreatic alpha cell differentiation in zebrafish. Dev Biol
2005; 285 (1): 211–23.
Nissen-Meyer LS, Jemtland R, Gautvik VT, Pedersen ME, Paro R, Fortunati D, Pierroz DD, Stadelmann VA, Reppe S, Reinholt FP, Del Fattore A, Rucci N, Teti A, Ferrari S, Gautvik KM. Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice. J Cell Sci
2007; 120(Pt 16): 2785–95.
Cheung M, Abu-Elmagd M, Clevers H, Scotting PJ. Roles of Sox4 in central nervous system development. Brain Res Mol Brain Res
2000; 79 (1-2): 180–91.
Bhattaram P, Penzo-Mendez A, Sock E, Colmenares C, Kaneko KJ, Vassilev A, Depamphilis ML, Wegner M, Lefebvre V. Organogenesis relies on SoxC transcription factors for the survival of neural and mesenchymal progenitors. Nat Commun
2010; 1: 9.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A
2004; 101 (25): 9309–14.
Bao ZQ, Zhang CC, Xiao YZ, Zhou JS, Tao YS, Chai DM. Over-expression of Sox4 and beta-catenin is associated with a less favorable prognosis of osteosarcoma. J Huazhong Univ Sci Technolog Med Sci
2016; 36 (2): 193–9.
Deneault E, Cellot S, Faubert A, Laverdure JP, Frechette M, Chagraoui J, Mayotte N, Sauvageau M, Ting SB, Sauvageau G. A functional screen to identify novel effectors of hematopoietic stem cell activity. Cell
2009; 137 (2): 369–79.
Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell
2010; 140 (1): 62–73.
Kobielak K, Stokes N, de la Cruz J, Polak L, Fuchs E. Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling. Proc Natl Acad Sci U S A
2007; 104 (24): 10063–8.
Lee AK, Ahn SG, Yoon JH, Kim SA. Sox4 stimulates ss-catenin activity through induction of CK2. Oncol Rep
2011; 25 (2): 559–65.
Hur W, Rhim H, Jung CK, Kim JD, Bae SH, Jang JW, Yang JM, Oh ST, Kim DG, Wang HJ, Lee SB, Yoon SK. SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro
2010; 31 (7): 1298–307.
Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res
2009; 69 (2): 709–17.
de Bont JM, Kros JM, Passier MM, Reddingius RE, Sillevis Smitt PA, Luider TM, den Boer ML, Pieters R. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol
2008; 10 (5): 648–60.
Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G, Jensen KM, Dyrskjot L, Orntoft T. SOX4 expression in bladder carcinoma: clinical aspects and in vitro
functional characterization. Cancer Res
2006; 66 (7): 3434–42.
Jafarnejad SM, Wani AA, Martinka M, Li G. Prognostic significance of Sox4 expression in human cutaneous melanoma and its role in cell migration and invasion. Am J Pathol
2010; 177 (6): 2741–52.
Jafarnejad SM, Ardekani GS, Ghaffari M, Martinka M, Li G. Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion. Oncogene
2013; 32 (17): 2131–9.
Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S, Yokota J, Gonzalez-Neira A, Benitez J, Clevers HC, Cigudosa JC, Lazo PA, Sanchez-Cespedes M. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet
2009; 18 (7): 1343–52.
Bruch J, Schulz WA, Haussler J, Melzner I, Bruderlein S, Moller P, Kemmerling R, Vogel W, Hameister H. Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. Cancer Res
2000; 60 (16): 4526–30.
Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med
2006; 354 (3): 270–82.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell
2004; 116 (2): 281–97.
Malan-Muller S, Hemmings SM, Seedat S. Big effects of small RNAs: a review of microRNAs in anxiety. Mol Neurobiol
2013; 47 (2): 726–39.
Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol
2011; 223 (2): 102–15.
Garzon R, Marcucci G. Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol
2012; 24 (6): 655–9.
Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res
2007; 67 (6): 2456–68.
Huang N, Wu Z, Lin L, Zhou M, Wang L, Ma H, Xia J, Bin J, Liao Y, Liao W. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget
2015; 6 (17): 15222–34.
Wen C, Liu X, Ma H, Zhang W, Li H. miR3383p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2. Int J Oncol
2015; 46 (5): 2277–85.
Jin Y, Zhao M, Xie Q, Zhang H, Wang Q, Ma Q. MicroRNA-338-3p functions as tumor suppressor in breast cancer by targeting SOX4. Int J Oncol
2015; 47 (4): 1594–602.
Sun K, Su G, Deng H, Dong J, Lei S, Li G. Relationship between miRNA-338-3p expression and progression and prognosis of human colorectal carcinoma. Chin Med J (Engl)
2014; 127 (10): 1884–90.
Li Y, Chen P, Zu L, Liu B, Wang M, Zhou Q. MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4. Am J Cancer Res
2016; 6 (2): 127–40.
Sun J, Feng X, Gao S, Xiao Z. microRNA-338-3p functions as a tumor suppressor in human nonsmallcell lung carcinoma and targets Ras-related protein 14. Mol Med Rep
2015; 11 (2): 1400–6.
Tong Z, Meng X, Wang J, Wang L. MicroRNA3383p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma. Exp Ther Med
2017; 14 (5): 5200–6.
Li P, Chen X, Su L, Li C, Zhi Q, Yu B, Sheng H, Wang J, Feng R, Cai Q, Li J, Yu Y, Yan M, Liu B, Zhu Z. Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One
2013; 8 (6): e66782.
Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res
2008; 68 (20): 8191–4.
Caiazza C, Mallardo M. The roles of miR-25 and its targeted genes in development of human cancer. Microrna
2016; 5 (2): 113–9.
Xiang J, Hang JB, Che JM, Li HC. MiR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7. Int J Clin Exp Pathol
2015; 8 (8): 9147–53.
Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, Zhang J, Peng C, Lin Y, Chen J. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget
2014; 5 (16): 7013–26.
Feng S, Pan W, Jin Y, Zheng J. MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2. Tumour Biol
2014; 35 (12): 12339–44.
Qiu G, Fang B, Xin G, Wei Q, Yuan X, Wu D. miR-25 promotes cell proliferation by targeting RECK in human cervical carcinoma HeLa cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
2015; 31 (1): 40–3.
Zhao H, Wang Y, Yang L, Jiang R, Li W. MiR-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem
2014; 385 (1-2): 207–13.
Li Q, Zou C, Zou C, Han Z, Xiao H, Wei H, Wang W, Zhang L, Zhang X, Tang Q, Zhang C, Tao J, Wang X, Gao X. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett
2013; 335 (1): 168–74.
Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, Kim T, Bakacs A, Alder H, Kaur B, Aqeilan RI, Pichiorri F, Croce CM. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci U S A
2012; 109 (14): 5316–21.
Chen B, Liu J, Qu J, Song Y, Li Y, Pan S. MicroRNA-25 suppresses proliferation, migration, and invasion of osteosarcoma by targeting SOX4. Tumour Biol
2017; 39 (7): 1010428317703841.
Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, Shen S. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget
2016; 7 (29): 45370–84.
Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, Wang H, Wang S, Su J, Lv X, Liu H, Du W, Zhou W, Chen X, Fei K. MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem
2013; 31 (1): 56–65.
Li D, He C, Wang J, Wang Y, Bu J, Kong X, Sun D. MicroRNA-138 inhibits cell growth, invasion, and EMT of non-small cell lung cancer via SOX4/p53 feedback loop. Oncol Res
2017. doi: 10.3727/096504017x14973124850905.
Yeh YM, Chuang CM, Chao KC, Wang LH. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int J Cancer
2013; 133 (4): 867–78.
Zhang P, Li J, Song Y, Wang X. MiR-129-5p inhibits proliferation and invasion of chondrosarcoma cells by regulating SOX4/Wnt/beta-catenin signaling pathway. Cell Physiol Biochem
2017; 42 (1): 242–53.
Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol
2016; 99: 141–9.
Bhattaram P, Penzo-Mendez A, Kato K, Bandyopadhyay K, Gadi A, Taketo MM, Lefebvre V. SOXC proteins amplify canonical WNT signaling to secure nonchondrocytic fates in skeletogenesis. J Cell Biol
2014; 207 (5): 657–71.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A
2004; 101 (9): 2999–3004.
Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer
2009; 125 (11): 2737–43.
Chen X, Zhang L, Zhang T, Hao M, Zhang X, Zhang J, Xie Q, Wang Y, Guo M, Zhuang H, Lu F. Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int
2013; 33 (3): 476–86.
Shen R, Pan S, Qi S, Lin X, Cheng S. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun
2010; 394 (4): 1047–52.
Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang TH. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res
2009; 69 (23): 9038–46.
Kang M, Li Y, Liu W, Wang R, Tang A, Hao H, Liu Z, Ou H. miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. Int J Mol Med
2013; 32 (1): 51–8.
Sandbothe M, Buurman R, Reich N, Greiwe L, Vajen B, Gürlevik E, Schäffer V, Eilers M, Kühnel F, Vaquero A, Longerich T, Roessler S, Schirmacher P, Manns M, Illig T, Schlegelberger B, Skawran B. The microRNA-449 family inhibits TGF-b-mediated liver cancer cell migration by targeting SOX4. J Hepatol
2017; 66 (5): 1012–21.
Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene
2009; 28 (14): 1714–24.
Chen H, Lin YW, Mao YQ, Wu J, Liu YF, Zheng XY, Xie LP. MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. Cancer Lett
2012; 320 (1): 40–7.
Ren XS, Yin MH, Zhang X, Wang Z, Feng SP, Wang GX, Luo YJ, Liang PZ, Yang XQ, He JX, Zhang BL. Tumor-suppressive microRNA-449a induces growth arrest and senescence by targeting E2F3 in human lung cancer cells. Cancer Lett
2014; 344 (2): 195–203.
Ming J, Zhou Y, Du J, Fan S, Pan B, Wang Y, Fan L, Jiang J. miR-381 suppresses C/EBPalpha-dependent Cx43 expression in breast cancer cells. Biosci Rep
2015; 35 (6). pii: e00266.
Tzeng HE, Chen PC, Lin KW, Lin CY, Tsai CH, Han SM, Teng CL, Hwang WL, Wang SW, Tang CH. Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cell-primed angiogenesis. Clin Sci (Lond)
2015; 129 (2): 147–58.
Li Y, Zhao C, Yu Z, Chen J, She X, Li P, Liu C, Zhang Y, Feng J, Fu H, Wang B, Kuang L, Li L, Lv G, Wu M. Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma. Oncotarget
2016; 7 (42): 68585–96.
Xia B, Li H, Yang S, Liu T, Lou G. MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumour Biol
2016; 37 (7): 9157–67.
Zhang M, Huang S, Long D. MiR381 inhibits migration and invasion in human gastric carcinoma through downregulatedting SOX4. Oncol Lett
2017; 14 (3): 3760–6.
Zhang B, Yin Y, Hu Y, Zhang J, Bian Z, Song M, Hua D, Huang Z. MicroRNA-204-5p inhibits gastric cancer cell proliferation by downregulating USP47 and RAB22A. Med Oncol
2015; 32 (1): 331.
Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan H, Xu S. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. Int J Mol Med
2015; 36 (6): 1720–6.
Sun Y, Yu X, Bai Q. miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer. Int J Clin Exp Pathol
2015; 8 (10): 12775–83.
Zhang L, Wang X, Chen P. MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells. BMC Cancer
2013; 13: 290.
Liu Z, Long J, Du R, Ge C, Guo K, Xu Y. miR-204 regulates the EMT by targeting snai1 to suppress the invasion and migration of gastric cancer. Tumour Biol
2016; 37 (6): 8327–35.
Yuan X, Wang S, Liu M, Lu Z, Zhan Y, Wang W, Xu AM. Histological and pathological assessment of miR-204 and SOX4 levels in gastric cancer patients. Biomed Res Int
2017; 2017: 6894675.
Zhou X, Li L, Su J, Zhang G. Decreased miR-204 in H. pylori
-associated gastric cancer promotes cancer cell proliferation and invasion by targeting SOX4. PLoS One
2014; 9 (7): e101457.
Yin JJ, Liang B, Zhan XR. MicroRNA-204 inhibits cell proliferation in T-cell acute lymphoblastic leukemia by down-regulating SOX4. Int J Clin Exp Pathol
2015; 8 (8): 9189–95.
Vishnubalaji R, Hamam R, Yue S, Al-Obeed O, Kassem M, Liu FF, Aldahmash A, Alajez NM. MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1. Oncotarget
2016; 7 (24): 35789–802.
Hu F, Min J, Cao X, Liu L, Ge Z, Hu J, Li X. MiR-363-3p inhibits the epithelial-to-mesenchymal transition and suppresses metastasis in colorectal cancer by targeting Sox4. Biochem Biophys Res Commun
2016; 474 (1): 35–42.
Zhang F, Luo Y, Shao Z, Xu L, Liu X, Niu Y, Shi J, Sun X, Liu Y, Ding Y, Zhao L. MicroRNA-187, a downstream effector of TGFbeta pathway, suppresses Smad-mediated epithelial-mesenchymal transition in colorectal cancer. Cancer Lett
2016; 373 (2): 203–13.
Sharma S, Nagpal N, Ghosh PC, Kulshreshtha R. P53-miR-191-SOX4 regulatory loop affects apoptosis in breast cancer. RNA
2017; 23 (8): 1237–46.
Nakahama T, Hanieh H, Nguyen NT, Chinen I, Ripley B, Millrine D, Lee S, Nyati KK, Dubey PK, Chowdhury K, Kawahara Y, Kishimoto T. Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation. Proc Natl Acad Sci U S A
2013; 110 (29): 11964–9.
Tian H, Hou L, Xiong YM, Huang JX, Zhang WH, Pan YY, Song XR. miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells. Am J Transl Res
2016; 8 (3): 1492–501.
Li Y, Zu L, Wang Y, Wang M, Chen P, Zhou Q. miR-132 inhibits lung cancer cell migration and invasion by targeting SOX4. J Thorac Dis
2015; 7 (9): 1563–9.
Lin L, Wang Z, Jin H, Shi H, Lu Z, Qi Z. MiR-212/132 is epigenetically downregulated by SOX4/EZH2-H3K27me3 feedback loop in ovarian cancer cells. Tumor Biol
2016; 37 (12): 15719–27.
Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F. The polycomb group protein EZH2 directly controls DNA methylation. Nature
2006; 439 (7078): 871–4.
Cao R, Zhang Y. The functions of E (Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev
2004; 14 (2): 155–64.
Liu Y, Li Y, Liu J, Wu Y, Zhu Q. MicroRNA-132 inhibits cell growth and metastasis in osteosarcoma cell lines possibly by targeting Sox4. Int J Oncol
2015; 47 (5): 1672–84.
Xia B, Yang S, Liu T, Lou G. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting cyclin D1 and CDK6. Mol Cancer
2015; 14: 57.
Jiang G, Cui Y, Yu X, Wu Z, Ding G, Cao L. miR-211 suppresses hepatocellular carcinoma by downregulating SATB2. Oncotarget
2015; 6 (11): 9457–66.
Song GQ, Zhao Y. MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration. Tumour Biol
2015; 36 (7): 5001–9.
Cai K, Shen F, Cui JH, Yu Y, Pan HQ. Expression of miR-221 in colon cancer correlates with prognosis. Int J Clin Exp Med
2015; 8 (2): 2794–8.
Wang CY, Hua L, Sun J, Yao KH, Chen JT, Zhang JJ, Hu JH. MiR-211 inhibits cell proliferation and invasion of gastric cancer by down-regulating SOX4. Int J Clin Exp Pathol
2015; 8 (11): 14013–20.
Tsukamoto O, Miura K, Mishima H, Abe S, Kaneuchi M, Higashijima A, Miura S, Kinoshita A, Yoshiura K, Masuzaki H. Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecol Oncol
2014; 132 (3): 715–21.
Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, Quint K, Ocker M, Di Fazio P. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog
2015; 54 (8): 585–97.
Yu Y, Cao L, Yang L, Kang R, Lotze M, Tang D. microRNA 30A promotes autophagy in response to cancer therapy. Autophagy
2012; 8 (5): 853–5.
Lu N, Lin T, Wang L, Qi M, Liu Z, Dong H, Zhang X, Zhai C, Wang Y, Liu L, Xiang L, Qi L, Han B, Li J. Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma. Tumour Biol
2015; 36 (5): 3843–52.
Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, Yang M, Han B. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun
2014; 452 (3): 746–52.
Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J, Lodish HF. Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J
2010; 24 (9): 3427–37.
Guo J, Xia B, Meng F, Lou G. miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor. Tumour Biol
2014; 35 (2): 1557–64.
Zheng K, Liu W, Liu Y, Jiang C, Qian Q. MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1. Oncol Lett
2015; 9 (2): 869–74.
Wei Z, An T, Wang Z, Chen K, Bai H, Zhu G, Duan J, Wu M, Yang L, Zhuo M, Wang Y, Liu X, Wang J. Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors. Thorac Cancer
2014; 5 (2): 126–32.
Cui W, Zhang S, Shan C, Zhou L, Zhou Z. microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. FEBS J
2013; 280 (16): 3962–74.
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin C, Zhang W. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep
2012; 27 (6): 1967–75.
Akanuma N, Hoshino I, Akutsu Y, Murakami K, Isozaki Y, Maruyama T, Yusup G, Qin W, Toyozumi T, Takahashi M, Suito H, Hu X, Sekino N, Matsubara H. MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. Br J Cancer
2014; 110 (1): 189–98.
Li S, Qin X, Li Y, Zhang X, Niu R, Zhang H, Cui A, An W, Wang X. MiR-133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4. Am J Transl Res
2015; 7 (8): 1390–403.
Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol
2007; 31 (2): 277–83.
Liu N, Tu Y. Systematic review of MicroRNAs and its therapeutic potential in glioma. Cancer Transl Med
2015; 1 (2): 50–66.
Qu W, Fei M, Xu B. Role of exosome microRNA in breast cancer. Cancer Transl Med
2017; 3 (5): 167–73.
Zou J, Xu Y. MicroRNA-140 inhibits cell proliferation in gastric cancer cell line HGC-27 by suppressing SOX4. Med Sci Monit
2016; 22: 2243–52.
[Figure 1], [Figure 2]
[Table 1], [Table 2]